Retatrutide
An advanced research peptide attracting considerable interest in metabolic and body composition studies. Retatrutide is a triple-agonist compound supplied in premium lyophilised format, subject to stringent quality control at every stage — from synthesis to dispatch.
What is Retatrutide?
Retatrutide is an investigational research peptide described as a multi-receptor agonist acting at the GIP, GLP-1 and glucagon receptors. It is supplied here in premium lyophilised form for laboratory research use only, and remains an investigational compound studied in preclinical settings.
Areas of research interest
Published preclinical research has explored Retatrutide in connection with:
- Metabolic-pathway research in cell and animal models
- Body-composition research in animal models
- Multi-receptor (GIP / GLP-1 / glucagon) signalling research
Research context
Laboratory and animal studies have investigated Retatrutide in the context of GIP, GLP-1 and glucagon receptor signalling. These observations are derived from preclinical research and have not been established in humans. This information is provided solely as a research reference.
Specifications
- 30mg vial
- Lyophilised powder
- Premium quality formulation
- Secure packaging
- UK dispatch
Quality Assurance
Every Syngeve compound is independently tested and supplied with a certificate of analysis. Average purity 99%+.
Certificate of Analysis
Independent third-party HPLC analysis. Every shipment includes the certificate for its specific batch.
Shipping
Dispatched within 24 hours in discreet, tamper-evident, insulated packaging.
For research purposes only, where permitted by local regulations. Not for human consumption. This product is not a medicine and is not intended to diagnose, treat, cure, or prevent any disease.
